NYSE:DHR News 1 December 2025 - 2 February 2026

Danaher shares closed up 2.1% at $223.42 Monday, ending a four-day slide and holding steady after hours. The company forecasts 2026 core revenue growth of 3% to 6% and adjusted EPS of $8.35 to $8.50. Investors are watching for signs of renewed lab and pharma spending amid a U.S. government shutdown that has delayed key economic data.

Danaher shares fell 2.2% to $219.49 Thursday after its 2026 profit outlook matched analyst estimates. Fourth-quarter revenue rose 4.5% to $6.8 billion, with adjusted earnings at $2.23 per share. CEO Rainer Blair said China diagnostics revenue declined only slightly in Q4, improving from previous quarters. Investors remain cautious as sector peers warn of continued weakness in academic research spending.

Danaher shares fell 4.8% to $224.54 after its 2026 profit outlook matched analyst expectations. The company beat fourth-quarter profit and revenue estimates, posting $6.8 billion in revenue and $2.23 per share in adjusted earnings. Trading volume more than doubled its 50-day average. Investors focused on the pace of recovery and upcoming results from rival Thermo Fisher.

Danaher shares closed down 0.42% at $235.60 Wednesday, then edged up 0.16% after hours. CEO Rainer Blair will present at the J.P. Morgan Healthcare Conference Jan. 13, with Q4 earnings set for Jan. 28. Evercore ISI and TD Cowen raised price targets to $250 and $270, respectively. The stock traded between $233.26 and $238.00, with 2.7 million shares changing hands.

Danaher Corporation (NYSE: DHR) is back in the spotlight on December 4, 2025, as fresh bullish research, new institutional buying, and a high‑profile Morgan Stanley upgrade collide with a series of governance investigations into the company’s board. At the same time, Danaher’s own guidance points to a 2026 recovery built on mid‑single‑digit revenue growth and expanding margins. As of Thursday afternoon, Danaher shares are trading around $227–$229, just below Wednesday’s close of $228.46, with today’s range roughly $227.60 to $230.65.StockAnalysis+2Investing.com+2 The stock sits about 11–12% below its 52‑week high of $258.23, but well above the $171.00 low, reflecting a sharp

Danaher Corporation (NYSE: DHR) enters December 2025 trading around the mid‑$220s per share, a high‑quality life‑sciences and diagnostics name that continues to command a premium valuation — and attract both bullish analysts and governance‑focused law firms.TS2+1 Below is a detailed, news‑driven overview of Danaher’s latest stock performance, legal and institutional developments, analyst forecasts and key themes to watch into 2026. Danaher stock today: price, valuation and trading context As of the U.S. session on December 1, 2025, Danaher is trading around $225 per share, with recent real‑time quotes in the ~$225–$225.50 range.MarketScreener Recent trading and valuation context: Danaher also pays